Charles River Laboratories International Inc., founded in 1947 and headquartered in Wilmington, Massachusetts, United States, is a premier contract research organization providing comprehensive preclinical and clinical laboratory services. The company’s flagship offerings include in vivo and in vitro testing, toxicology studies, and integrated preclinical development solutions under its CRL Discovery Services. Under the leadership of CEO James C. Foster since 2017, CRL has secured a leading position in the global CRO market with an estimated 15% market share in its preclinical segment. Focused on digital transformation and strategic growth initiatives, the company is poised to achieve an anticipated annual revenue growth of 8-10%.